E
Edward L. Trimble
Researcher at National Institutes of Health
Publications - 152
Citations - 11460
Edward L. Trimble is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & Cervical cancer. The author has an hindex of 43, co-authored 149 publications receiving 10418 citations. Previous affiliations of Edward L. Trimble include Hospital Italiano de Buenos Aires & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
TL;DR: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables.
Journal ArticleDOI
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Joy H Lewis,Meredith L. Kilgore,Dana P. Goldman,Edward L. Trimble,Richard Kaplan,Michael Montello,Michael G. Housman,Jose Escarce +7 more
TL;DR: The elderly are underrepresented in cancer clinical trials relative to their disease burden, and older patients are more likely to have medical histories that make them ineligible for clinical trials because of protocol exclusions.
Journal ArticleDOI
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman,Mark F. Brady,William McGuire,Peter Harper,David S. Alberts,Michael Friedlander,Nicoletta Colombo,Jeffrey M. Fowler,Peter A. Argenta,Koen De Geest,David G. Mutch,Robert A. Burger,Ann Marie Swart,Edward L. Trimble,Chrisann Accario-Winslow,Lawrence M. Roth +15 more
TL;DR: Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction as well as survival analyses of groups defined by size of residual disease.
Journal ArticleDOI
Ovarian Cancer: Screening, Treatment, and Follow-up
Vicki L. Seltzer,Bruce H. Drukker,Brenda W. Gillespie,Lynn M. Gossfeld,Perry W. Grigsby,Harold A. Harvey,Carolyn B. Hendricks,Sherilynn Hummel,Robert W. Makuch,Grace Powers Monaco,Groesbeck P. Parham,Charles L. Sawyers,Randal J. West,David S. Alberts,Barrie Anderson,Hervy E. Averette,Robert C. Bast,Michaele C. Christian,Nicoletta Colombo,William T. Creasman,John P. Curtin,David M. Gershenson,William J. Hoskins,Beth Y. Karlan,Barnett S. Kramer,Maurie Markman,William McGuire,Robert F. Ozols,Sergio Pecorelli,Karl C. Podratz,J. Tate Thigpen,Gillian M. Thomas,Cornelia L. Trimble,Carolyn Westhoff,Alice S. Whittemore,Robert C. Young,Edward L. Trimble,Elaine Blume,Elsa A. Bray,John H. Ferguson,Ruthann Giusti,William J. Hall,Charles Harrison,Mary McCabe,Timothy Moore,Susan G. Nayfield,Cherie Nichols,Robert C. Park,Eddie Reed,Charles B. Sherman,Samuel Broder,John H. Ferguson +51 more
TL;DR: There is no evidence available yet that the current screening modalities of CA 125 and transvaginal ultrasonography can be effectively used for widespread screening to reduce mortality from ovarian cancer nor that their use will result in decreased rather than increased morbidity and mortality.
Journal ArticleDOI
Interim Guidelines for Management of Abnormal Cervical Cytology
Robert J. Kurman,Donald Eari Henson,Arthur L. Herbst,Kenneth L. Noller,Mark Schiffman,Thomas A. Bonfiglio,Henry W. Buck,Christopher P. Crum,John P. Curtin,Mitchell D. Greenberg,Kenneth D. Hatch,Donald E. Henson,A. Bennett Jenson,Peter R. Johnson,Howard W. Jones,Harold A. Kaminetsky,Luella Klein,Leopold G. Koss,Burton A. Krumholz,Nancy C. Lee,Ronald D. Luff,Jeanne S. Mandelblatt,Richard Reid,Ralph M. Richart,Thomas V. Sedlacek,Charles Sneiderman,Diane Solomon,Mark H. Stoler,Floyd Taub,Edward L. Trimble,Ernest F. Tucker,Leo B. Twiggs,Edward J. Wilkinson,Barbara Atkinson,Harvey E. Averette,William T. Creasman,Sandra Fryhofer,Julie Noy,Mary L. Nielsen,Kenneth L. Noller,Robert C. Park,Douglas Westhoff +41 more
TL;DR: In recent years it has become evident that the cost and morbidity associated with the detection and treatment of low-grade cervical lesions have escalated, probably increasing the likelihood of women developing cervical cancer.